Literature DB >> 11470707

Vigabatrin effect on inner retinal function.

S G Coupland1, D H Zackon, B C Leonard, T M Ross.   

Abstract

OBJECTIVE: To determine the degree of electroretinal dysfunction in a group of patients taking Vigabatrin (VGB). Additionally, to investigate the role of cumulative dosage, the role of VGB alone or in combination with other anticonvulsants, and whether recent discontinuance of VGB affects electroretinal function as measured by the electroretinogram (ERG).
DESIGN: Retrospective, comparative case series. PARTICIPANTS: Forty patients (18 male, 22 female) with a mean age of 35 years were studied as three groups: the VGB multitherapy group (n = 24) included those taking VGB with other anticonvulsants, the VGB monotherapy group (n = 9) included those taking VGB alone, and the off-VGB group (n = 7) included those who had discontinued VGB in the last 6 months.
METHODS: Scotopic flash, photopic flash, and 30-Hz flicker ERG results were recorded according to the International Society for Clinical Electrophysiology of Vision (ISCEV) standard. The clinical electro-oculogram (EOG) results were recorded according to the ISCEV standard. MAIN OUTCOME MEASURES: Implicit time and amplitudes of the A- and B-waves of the flash and 30-Hz flicker ERGs were recorded. Summed amplitude of the first three oscillatory potential wavelets were recorded. The light-peak to-dark-trough Arden ratio of the EOG was evaluated.
RESULTS: Although photopic ERG B-wave reduction was most frequent in patients in the VGB multitherapy group (48% of eyes), a significant number of eyes in all three groups had scotopic ERG B-wave reduction. The 30-Hz flicker ERG result was abnormally reduced in all three groups. There was no significant difference in the frequency of occurrence in ERG result abnormalities between the VGB monotherapy and VGB multitherapy groups. The EOG results revealed reduced Arden ratios in all three groups; however, there was a significantly lower frequency of EOG abnormalities noted in the off-VGB group (P = 0. 0373). There was no statistically significant relationship between the frequency of electrodiagnostic abnormalities and the duration of use or the total cumulative dosage of Vigabatrin in any of the three groups.
CONCLUSIONS: These findings of scotopic ERG result abnormalities suggest that VGB alone has an effect on inner electroretinal function at the level of the Müller cell. Concomitant EOG abnormalities suggest a substantial effect of VGB on outer retinal function that may be reversible after cessation of VGB treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470707     DOI: 10.1016/s0161-6420(01)00638-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  18 in total

1.  Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.

Authors:  Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

2.  The effect of GABA and the GABA-uptake-blocker NO-711 on the b-wave of the ERG and the responses of horizontal cells to light.

Authors:  Renate Hanitzsch; Lea Küppers; Andreas Flade
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

3.  Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.

Authors:  John M Wild; David L Fone; Saleh Aljarudi; Charlotte Lawthom; Philip E M Smith; Robert G Newcombe; Gareth D Lewis
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

4.  Retinal function and histopathology in rabbits treated with Topiramate.

Authors:  S Kjellström; A Bruun; B Isaksson; T Eriksson; S Andréasson; V Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-11-18       Impact factor: 2.379

5.  Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow.

Authors:  S L Hosking; E J Roff Hilton; S J Embleton; A K Gupta
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

6.  Electroretinographic (ERG) responses in pediatric patients using vigabatrin.

Authors:  Anne Moskowitz; Ronald M Hansen; Susan E Eklund; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2012-03-20       Impact factor: 2.379

7.  Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients.

Authors:  Betül Tuğcu; Mesrure Köseoğlu Bitnel; Fatma Selin Kaya; Betül Tekin Güveli; Dilek Ataklı
Journal:  Neurol Sci       Date:  2017-05-16       Impact factor: 3.307

8.  Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.

Authors:  Sivan Durbin; Giuseppe Mirabella; J Raymond Buncic; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-11       Impact factor: 4.799

9.  Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin.

Authors:  Vesna Ponjavic; Lotta Gränse; Sten Kjellström; Sten Andréasson; Anitha Bruun
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

10.  Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina.

Authors:  Qing-Ping Wang; Firas Jammoul; Agnès Duboc; Jie Gong; Manuel Simonutti; Elisabeth Dubus; Cheryl M Craft; Wen Ye; José A Sahel; Serge Picaud
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.